title: Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids.
abstract: In humans, genetic variation occurs through different types of alleles that vary in frequency and severity of effect. Mendelian mutations, such as those in the low-density lipoprotein (LDL) receptor (LDLR) that result in familial hypercholesterolemia, are rare and have powerful phenotypic effects. Conversely, alleles that are common in the population (such that homozygotes for the minor allele are present even in modest sample sizes) typically have very modest phenotypic effects. In the middle of the spectrum are "Goldilocks" alleles such as mutations in the gene for proprotein convertase subtilisin/kexin type 9 (PCSK9). Loss-of-function mutations in PCSK9 result in significantly decreased LDL-cholesterol levels and a disproportionately large reduction in coronary heart disease risk by reducing the exposure to LDL-cholesterol throughout life. Several agents to inhibit PCSK9 are currently in development, demonstrating the potential utility of translating genetics into clinical therapeutics. To date, most investigations aimed at identifying the genes responsible for hypercholesterolemia have used linkage analysis, which requires samples collected from multiple families with defects in the same gene, or common variant analysis which requires thousands of samples from the population. However, case studies have shown that with advances in whole genome sequencing or exome sequencing (targeted exome capture), the process of discovering causal genetic mutations can be significantly streamlined. Astute clinical observation of individual patients and their families with atypical lipid profiles, followed by sequencing of the affected individual, has the potential to lead to important findings regarding the genetic mutations that cause lipid abnormalities.
authors: Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. jonathan.cohen@utsouthwestern.edu
authors: Jonathan C
authors: JC
authors: Cohen
mesh_terms: D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D005826:Genetics, Medical / Q000379:methods; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000235:genetics; D012697:Serine Endopeptidases / Q000235:genetics
chemical_list: D008078:Cholesterol, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases
references: J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17
references: 21600530
references: Curr Opin Lipidol. 2011 Apr;22(2):123-8
references: 21311327
references: Nat Genet. 2005 Feb;37(2):161-5
references: 15654334
references: Cell Mol Life Sci. 2005 Jun;62(12):1372-8
references: 15818469
references: Am J Hum Genet. 2006 Mar;78(3):410-22
references: 16465619
references: Vasc Health Risk Manag. 2008;4(1):39-57
references: 18629371
references: Lancet. 2007 Mar 31;369(9567):1078; author reply 1079
references: 17398299
references: Am J Epidemiol. 2002 Mar 15;155(6):487-95
references: 11882522
references: Curr Opin Lipidol. 2012 Apr;23(2):98-103
references: 22418572
references: N Engl J Med. 2010 Dec 2;363(23):2220-7
references: 20942659
references: Proc Natl Acad Sci U S A. 1987 Oct;84(19):6919-23
references: 3477815
references: Atherosclerosis. 2003 May;168(1):1-14
references: 12732381
references: Circulation. 2002 Dec 17;106(25):3143-421
references: 12485966
references: PLoS One. 2008 Aug 20;3(8):e2986
references: 18714375
references: Curr Opin Lipidol. 2003 Apr;14(2):121-7
references: 12642779
references: N Engl J Med. 2006 Mar 23;354(12):1264-72
references: 16554528
references: Nat Genet. 2003 Jun;34(2):154-6
references: 12730697
references: J Med Liban. 1973 Apr;26(4):325-9
references: 4206463
references: N Engl J Med. 2012 Mar 22;366(12):1108-18
references: 22435370
references: Hum Mol Genet. 2010 Nov 15;19(22):4313-8
references: 20719861
references: Curr Opin Lipidol. 2001 Apr;12(2):141-9
references: 11264985
references: Nature. 2010 Aug 5;466(7307):707-13
references: 20686565
references: J Am Coll Cardiol. 2010 Jun 22;55(25):2833-42
references: 20579540
references: Atherosclerosis. 2007 Aug;193(2):445-8
references: 16989838
references: Lancet. 2012 Aug 11;380(9841):572-80
references: 22607825
references: Nat Genet. 2008 Feb;40(2):161-9
references: 18193043
references: Clin Genet. 2008 Jan;73(1):1-13
references: 18028451